In a double-blind study, rolipram, a new phosphodiesterase inhibitor, was com pared to placebo in 20 hospitalized depressed patients. There was a high rate of non- completion (11 out of 20) at 28 days. No difference was found in the clinical improvement between the two groups.
Get full access to this article
View all access options for this article.
References
1.
Carney M W P, Roth M., Garside R.F.1965The diagnosis of depressive syndromes and the prediction of ECT responseBritish Journal of Psychiatry3: 659-674
2.
Hamilton M.1967Development of a rating scale for primary depressive illnessBritish Journal of Social and Clinical Psychology6: 278-296
3.
Horowski R., Sastre-y-Hernandez M.1985Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reportsCurrent Therapeutic Research38: 123-29
4.
Kehr W., Debus G., Neumeister R.1985Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brainJournal of Neural Transmission663: 1-12
5.
The Lancet 1987 Drop-outs from clinical trialsThe Lancetii: 892-893
6.
Lasky T.1962The problems of sample attrition in controlled treatment trials. Journal of Nervous and Mental Diseases135: 332-337
7.
Markowitz J.S., Rabkin J.G., McGrath P.J., Stewart J., Quitkin F.M.1985Attrition and its consequences in a clinical trial of placebo, imipramine and phenelzinePsychopharmocology Bulletin21: no 1107-109
8.
Montgomery S.A., Asberg M.1979A new depression scale designed to be sensitive to changeBritish Journal of Psychiatry134: 382-389
9.
Morris J.B., Beck A.T.1974The efficacy of antidepressant drugsArchives of General Psychiatry30: 667-674
10.
Przegaliński E., Rawlow A.1982The stimulatory action of inhibitors of phosphodiesterase on the flexor reflex of the hind limb in the spinal ratJournal of Neural Transmission55: 9-17
11.
Rowlands M W D1987Recruitment to inpatient trials of antidepressantsThe Lanceti: 451-452
12.
Schwabe U., Miyake M., Ohga Y., Daly J.W.19764-(3-Cyclopentyloxy-4-methoxypenyl)-2-pyrrolidone (ZK 62 711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brainMolecular Pharmacology12: 900-910
13.
Wachtel H.1982Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitorsPsychopharmacology, 77: 309-316
14.
Wachtel H.1983Potential antidepressant activity of rolipram and other selective adenosine 3',5'-monophosphate phosphodiesterase inhibitorsNeuropharmacology, 22: 3A267-272
15.
Zeller E., Stief H-J., Pflug B., Sastre-y-Hernandez M.1984Results of a phase II study of the antidepressant effect of rolipramPharmacopsychiatry17: 188-190
